Cargando…

Markers of Aggressiveness in Craniopharyngiomas

Craniopharyngiomas (CP) are rare tumors that may be locally aggressive. The presence of functional estrogen receptors (ER) has been reported in CP and might be related to risk of recurrence. Our aim is to ascertain if the expression estrogen and progesterone receptor (PR) might be associated with to...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Can-Sanchez, Diego Jesús, Sanchez, Diego Jesus Del Can, Martínez-Ortega, Antonio Jesús, Flores-Martínez, Alvaro, Venegas-Moreno, Eva, Dios-Fuentes, María Elena, Madrazo-Atutxa, Ainara, Valdepeñas, Eugenio Cárdenas-Ruiz, Kaen, Ariel Matías, Márquez-Rivas, Francisco Javier, Roldán-Lora, Anastasia Florinda, Fajardo-Picó, Elena, Cano-González, David, Soto-Moreno, Alfonso
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090695/
http://dx.doi.org/10.1210/jendso/bvab048.1317
_version_ 1783687345329930240
author Del Can-Sanchez, Diego Jesús
Sanchez, Diego Jesus Del Can
Martínez-Ortega, Antonio Jesús
Flores-Martínez, Alvaro
Venegas-Moreno, Eva
Dios-Fuentes, María Elena
Madrazo-Atutxa, Ainara
Valdepeñas, Eugenio Cárdenas-Ruiz
Kaen, Ariel Matías
Márquez-Rivas, Francisco Javier
Roldán-Lora, Anastasia Florinda
Fajardo-Picó, Elena
Cano-González, David
Soto-Moreno, Alfonso
author_facet Del Can-Sanchez, Diego Jesús
Sanchez, Diego Jesus Del Can
Martínez-Ortega, Antonio Jesús
Flores-Martínez, Alvaro
Venegas-Moreno, Eva
Dios-Fuentes, María Elena
Madrazo-Atutxa, Ainara
Valdepeñas, Eugenio Cárdenas-Ruiz
Kaen, Ariel Matías
Márquez-Rivas, Francisco Javier
Roldán-Lora, Anastasia Florinda
Fajardo-Picó, Elena
Cano-González, David
Soto-Moreno, Alfonso
author_sort Del Can-Sanchez, Diego Jesús
collection PubMed
description Craniopharyngiomas (CP) are rare tumors that may be locally aggressive. The presence of functional estrogen receptors (ER) has been reported in CP and might be related to risk of recurrence. Our aim is to ascertain if the expression estrogen and progesterone receptor (PR) might be associated with to recurrence in CP. Material and Methods: Descriptive retrospective observational study of patients with confirmed histology of CP and tissue sample available admitted to Virgen Del Rocio University Hospital (Seville, Spain) from January 1967 to October 2020 were included. Estrogen and progesterone receptor expression was analyzed by Immunohistochemistry. Ki-67 levels were also analyzed. Two CP groups were considereded according to Ki67 levels: Group A (Ki67<10%) and group B (Ki67>10%). As all variables followed a non-parametric distribution, U Mann Whitney, Chi-Square, and Z-test with Benjamini-Hochberg correction were used when needed. Results: Our study population includes 80 patients (46 male and 34 female), with a median age at diagnosis of 34 years [10-50.00]. Twenty-six patients were under 18 years old (children) with a median age of 7 years [4.5-10.00], and 54 were adults (aged 18 and above) with a median age of 45 years [33-58.50]. Our data shows higher recurrence rates when Ki67 levels staining were higher than 10%: 8/14 (57.2%) in comparison with Ki67<10% (6/14, 42.9%, p=0.018). In children we found 6 samples with Ki67<10% and 6 samples with Ki67 >10%; recurrences were observed in 2/6 (33,3%) in the first group and in 6/6 (100%) in the second, respectively (p= 0,199). In adults, we found 9 and 3 patients for high and low Ki67 levels, respectively. Recurrences were observed in 4/9 (44,4%) in the group A and in 2/3 (66,7%) in the group B, respectively (p= 0,28). There were no differences between age groups. In patients with positive ER, we observed an increased rate of recurrence: 12/23 (52.17%) versus 2/13 (15,38%) in patients with negative ER stain but it was no significant. (p=0,21). No association between PR and recurrence was observed. Conclusions: In our series, patients with CP with high Ki67 levels are more likely to recur. No clear association between ER, PR expression and recurrence was observed. These findings support the use of Ki67 as a marker of recurrence in CP. Sources of Research Support: Spanish Ministry of Health, ISCIII co-funded with Fondos FEDER (PI16/00175) and Novartis Oncology Spain.
format Online
Article
Text
id pubmed-8090695
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-80906952021-05-12 Markers of Aggressiveness in Craniopharyngiomas Del Can-Sanchez, Diego Jesús Sanchez, Diego Jesus Del Can Martínez-Ortega, Antonio Jesús Flores-Martínez, Alvaro Venegas-Moreno, Eva Dios-Fuentes, María Elena Madrazo-Atutxa, Ainara Valdepeñas, Eugenio Cárdenas-Ruiz Kaen, Ariel Matías Márquez-Rivas, Francisco Javier Roldán-Lora, Anastasia Florinda Fajardo-Picó, Elena Cano-González, David Soto-Moreno, Alfonso J Endocr Soc Neuroendocrinology and Pituitary Craniopharyngiomas (CP) are rare tumors that may be locally aggressive. The presence of functional estrogen receptors (ER) has been reported in CP and might be related to risk of recurrence. Our aim is to ascertain if the expression estrogen and progesterone receptor (PR) might be associated with to recurrence in CP. Material and Methods: Descriptive retrospective observational study of patients with confirmed histology of CP and tissue sample available admitted to Virgen Del Rocio University Hospital (Seville, Spain) from January 1967 to October 2020 were included. Estrogen and progesterone receptor expression was analyzed by Immunohistochemistry. Ki-67 levels were also analyzed. Two CP groups were considereded according to Ki67 levels: Group A (Ki67<10%) and group B (Ki67>10%). As all variables followed a non-parametric distribution, U Mann Whitney, Chi-Square, and Z-test with Benjamini-Hochberg correction were used when needed. Results: Our study population includes 80 patients (46 male and 34 female), with a median age at diagnosis of 34 years [10-50.00]. Twenty-six patients were under 18 years old (children) with a median age of 7 years [4.5-10.00], and 54 were adults (aged 18 and above) with a median age of 45 years [33-58.50]. Our data shows higher recurrence rates when Ki67 levels staining were higher than 10%: 8/14 (57.2%) in comparison with Ki67<10% (6/14, 42.9%, p=0.018). In children we found 6 samples with Ki67<10% and 6 samples with Ki67 >10%; recurrences were observed in 2/6 (33,3%) in the first group and in 6/6 (100%) in the second, respectively (p= 0,199). In adults, we found 9 and 3 patients for high and low Ki67 levels, respectively. Recurrences were observed in 4/9 (44,4%) in the group A and in 2/3 (66,7%) in the group B, respectively (p= 0,28). There were no differences between age groups. In patients with positive ER, we observed an increased rate of recurrence: 12/23 (52.17%) versus 2/13 (15,38%) in patients with negative ER stain but it was no significant. (p=0,21). No association between PR and recurrence was observed. Conclusions: In our series, patients with CP with high Ki67 levels are more likely to recur. No clear association between ER, PR expression and recurrence was observed. These findings support the use of Ki67 as a marker of recurrence in CP. Sources of Research Support: Spanish Ministry of Health, ISCIII co-funded with Fondos FEDER (PI16/00175) and Novartis Oncology Spain. Oxford University Press 2021-05-03 /pmc/articles/PMC8090695/ http://dx.doi.org/10.1210/jendso/bvab048.1317 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Neuroendocrinology and Pituitary
Del Can-Sanchez, Diego Jesús
Sanchez, Diego Jesus Del Can
Martínez-Ortega, Antonio Jesús
Flores-Martínez, Alvaro
Venegas-Moreno, Eva
Dios-Fuentes, María Elena
Madrazo-Atutxa, Ainara
Valdepeñas, Eugenio Cárdenas-Ruiz
Kaen, Ariel Matías
Márquez-Rivas, Francisco Javier
Roldán-Lora, Anastasia Florinda
Fajardo-Picó, Elena
Cano-González, David
Soto-Moreno, Alfonso
Markers of Aggressiveness in Craniopharyngiomas
title Markers of Aggressiveness in Craniopharyngiomas
title_full Markers of Aggressiveness in Craniopharyngiomas
title_fullStr Markers of Aggressiveness in Craniopharyngiomas
title_full_unstemmed Markers of Aggressiveness in Craniopharyngiomas
title_short Markers of Aggressiveness in Craniopharyngiomas
title_sort markers of aggressiveness in craniopharyngiomas
topic Neuroendocrinology and Pituitary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090695/
http://dx.doi.org/10.1210/jendso/bvab048.1317
work_keys_str_mv AT delcansanchezdiegojesus markersofaggressivenessincraniopharyngiomas
AT sanchezdiegojesusdelcan markersofaggressivenessincraniopharyngiomas
AT martinezortegaantoniojesus markersofaggressivenessincraniopharyngiomas
AT floresmartinezalvaro markersofaggressivenessincraniopharyngiomas
AT venegasmorenoeva markersofaggressivenessincraniopharyngiomas
AT diosfuentesmariaelena markersofaggressivenessincraniopharyngiomas
AT madrazoatutxaainara markersofaggressivenessincraniopharyngiomas
AT valdepenaseugeniocardenasruiz markersofaggressivenessincraniopharyngiomas
AT kaenarielmatias markersofaggressivenessincraniopharyngiomas
AT marquezrivasfranciscojavier markersofaggressivenessincraniopharyngiomas
AT roldanloraanastasiaflorinda markersofaggressivenessincraniopharyngiomas
AT fajardopicoelena markersofaggressivenessincraniopharyngiomas
AT canogonzalezdavid markersofaggressivenessincraniopharyngiomas
AT sotomorenoalfonso markersofaggressivenessincraniopharyngiomas